The patient is not their LDL: the case for active follow-up
DOI:
https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v46i4.1388Keywords:
Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Cardiovascular Risk FactorsAbstract
Should statin therapy be recommended for a healthy young adult with persistently elevated LDL cholesterol levels? The editors of the Revista del Hospital Italiano de Buenos Aires invite readers to reflect on this debated topic through a hypothetical clinical scenario.
Dr. Karin Kopitowski presents her arguments regarding the use of cholesterol-lowering pharmacological treatment in young adults with low short-term cardiovascular risk and discusses the factors that should be considered when making this decision.
Read also Dr. Walter Masson’s commentary [link].
Downloads
References
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. DOI: https://doi.org/10.1093/eurheartj/ehx144 DOI: https://doi.org/10.1093/eurheartj/ehx144
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. DOI: https://doi.org/10.1161/CIR.0000000000001423 DOI: https://doi.org/10.1161/CIR.0000000000001423
Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-78. DOI: https://doi.org/10.1093/eurheartj/ehaf190 DOI: https://doi.org/10.1093/eurheartj/ehaf919
US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2022;328(8):746-53. DOI: https://doi.org/10.1001/jama.2022.13044 DOI: https://doi.org/10.1001/jama.2022.13044
Jamoulle M. Quaternary prevention, an answer of family doctors to overmedicalization. Int J Health Policy Manag. 2015;4(2):61-4. DOI: https://doi.org/10.15171/ijhpm.2015.24 DOI: https://doi.org/10.15171/ijhpm.2015.24
Downloads
Published
Data Availability Statement
Not applicable.Issue
Section
License
Copyright (c) 2026 Karin Kopitowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
